What is the recommended therapeutic hypothermia protocol for hypoxic‑ischemic encephalopathy in term neonates and in adults after cardiac arrest?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Therapeutic Hypothermia for Hypoxic-Ischemic Encephalopathy

For neonatal HIE, cool term infants (≥36 weeks) with moderate-to-severe encephalopathy to 33.5°C for 72 hours starting within 6 hours of birth; for adults after cardiac arrest, cool unconscious patients to 32-34°C for 12-24 hours when initial rhythm was ventricular fibrillation. 1, 2

Neonatal HIE Protocol

Patient Selection Criteria

Initiate therapeutic hypothermia for term neonates (≥36 weeks gestation) who meet ALL of the following within 6 hours of birth: 1

  • Biochemical evidence of peripartum hypoxic-ischemic event:

    • Cord blood gas with pH <7.0 or base deficit ≥16 mmol/L
    • If cord gas unavailable, obtain blood gas within first hour showing similar acidosis
  • Clinical evidence of moderate-to-severe encephalopathy:

    • Altered consciousness (lethargy, stupor, or coma)
    • Abnormal tone (hypotonia or hypertonia)
    • Abnormal reflexes (absent or weak suck, Moro reflex)
    • Clinical seizures

No sentinel event identification is required to initiate cooling. 1

Cooling Parameters

Target temperature: 33.5°C (rectal/esophageal) for exactly 72 hours 1

  • Deeper cooling (32°C) or longer duration (120 hours) increases mortality without improving outcomes 1
  • Rewarm slowly at 0.5°C per hour after 72 hours 3
  • Use servo-controlled devices to maintain precise temperature control

Timing Considerations

Optimal window: Initiate within 6 hours of birth 1

Late cooling (6-24 hours): May be considered with shared decision-making if infant initially didn't meet criteria or cooling was unavailable earlier. Evidence shows only 76% probability of modest benefit (1-3% reduction in death/disability). Cool for 96 hours if starting late. 1

Transport Cooling

Use servo-controlled cooling devices during transport when arrival at cooling center within 6 hours is not feasible. 1 Passive cooling (turning off radiant warmer, applying gel packs) carries significant overcooling risk and requires continuous rectal temperature monitoring every 15 minutes. 4

Special Populations

Late preterm infants (35 0/7 to 35 6/7 weeks): Limited evidence exists. Cooling may be considered only after detailed parental discussion documenting potential risks and uncertain benefits. 1

Mild HIE: Do NOT cool outside research protocols. Insufficient evidence of benefit. 1

Required Infrastructure

Centers offering therapeutic hypothermia must provide: 1

  • Mechanical ventilation capability
  • Continuous temperature and vital sign monitoring
  • Brain MRI before discharge
  • Continuous EEG monitoring (preferred) or amplitude-integrated EEG
  • 24/7 neurology consultation access
  • Written protocols with outcome monitoring
  • Neurodevelopmental follow-up programs

Critical Pitfalls to Avoid

  • Hyperthermia prevention: Even when not cooling, avoid fever in all suspected HIE cases 1
  • Overcooling: Temperature <32°C increases mortality; use servo-controlled devices 1
  • Delayed identification: Educate all delivery and nursery staff on eligibility criteria 1
  • Hypocarbia: Avoid during mechanical ventilation as it worsens outcomes 3

Adult Post-Cardiac Arrest Protocol

Cool unconscious adult patients with spontaneous circulation after out-of-hospital cardiac arrest to 32-34°C for 12-24 hours when initial rhythm was ventricular fibrillation. 2

Patient Selection

  • Unconscious after return of spontaneous circulation (ROSC)
  • Out-of-hospital cardiac arrest with witnessed VF as initial rhythm
  • May also benefit patients with other rhythms or in-hospital arrest, though evidence is weaker 2

Cooling Parameters

  • Target temperature: 32-34°C
  • Duration: 12-24 hours
  • Monitoring: Core temperature via bladder probe or pulmonary artery catheter (tympanic measurements unreliable) 2

Key Differences from Neonatal Cooling

The evidence for adult therapeutic hypothermia is substantially weaker and more inconsistent than neonatal data. 5, 6 Multiple factors explain this disparity:

  • Timing constraints: Adults often receive cooling beyond the critical 4-hour window when brain injury becomes irreversible 5, 7
  • Shorter treatment duration: Adult trials used 12-48 hours versus 72 hours in neonates 6
  • Comorbidities: Adults have diabetes, hypertension, atherosclerosis, and active inflammation that interfere with neuroprotection 6
  • Injury mechanism: Adult cardiac arrest involves more necrosis (which hypothermia doesn't prevent) versus neonatal apoptosis (which hypothermia inhibits) 6
  • Population heterogeneity: Patients with minimal injury don't need cooling; those with severe irreversible injury won't benefit. Only moderate-severity patients may respond. 7

Clinical Reality

Recent large trials show inconsistent benefit in adults, unlike the robust neonatal evidence. 5 The 2003 ILCOR recommendation 2 predates these negative trials. Current practice should focus on:

  • Ultra-early initiation (within 4 hours of ROSC if possible) 5, 7
  • Patient stratification using neuroimaging, EEG, and biomarkers to identify moderate-severity injury 7, 8
  • Avoiding fever in all comatose post-arrest patients regardless of cooling decision 5

Pediatric Considerations

Insufficient evidence exists for therapeutic hypothermia in children after cardiac arrest. 2 Historical data from near-drowning victims showed increased mortality with cooling, though these studies used deeper temperatures (30-33°C) for longer durations (36 hours) than current protocols. Tailor therapy individually based on risk-benefit assessment. 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.